Buy & Sell Sanofi SA (SNY) – Sanofi SA Price Today
Aura AI Summary
Key Stats
- $106.18BMarket Cap
- HealthSector
- -11.96%3M Drawdown
- $122.99BEnterprise Value
- 5.46%Dividend Yield
- 42% Buy | 58% SellTrading Activity
- 92 daysTypical Hold Time
Sanofi SA (SNY) is currently valued at a market capitalization of $106.18B, with an enterprise value of $122.99B. Over the past 52 weeks, Sanofi SA has traded between a low of $42.42 and a high of $52.35, highlighting its annual price range. Over the past three months, Sanofi SA has recorded a drawdown of -11.96%, reflecting recent price volatility. Sanofi SA offers a dividend yield of 5.46%, with the most recent dividend of $2.42 paid on 04 May 26. On average, investors hold Sanofi SA for approximately 92 days, indicating typical investor behavior on the platform.
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Most Recent News
Broadcom gains billionaire investor as AI chip demand boosts stock and revenue forecasts.
Hedge fund billionaire Daniel Loeb increased his stake in Broadcom by buying 50,000 shares while reducing holdings in NVIDIA and Taiwan Semiconductor. Broadcom reported strong Q1 revenue of $19.31 billion, beating estimates, and expects Q2 revenue ar...
Dow Jones hits record 51,000 as Dell surges 28% on strong AI sales and outlook
U.S. stocks reached new highs with the Dow Jones Industrial Average topping 51,000, driven by a 28% surge in Dell Technologies shares after a strong Q1 report. Dell reported $43.8 billion in revenue, up 88% year-over-year, with $24.4 billion in AI-re...
Photronics faces securities fraud probe after Q2 earnings miss, shares drop 36%.
Photronics, Inc. is under investigation by Glancy Prongay Wolke & Rotter LLP for possible securities law violations following its Q2 2026 earnings report. The company reported a revenue decline to $209 million and a drop in operating margins to 20.1%...
